NEW YORK, NY, December 15, 2023 – NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has reported additional positive efficacy data from its Phase 2b trial evaluating PrimeC, the company’s lead drug candidate for amyotrophic lateral sclerosis (ALS). The company’s share price rose nearly 30% in trading on Thursday. Alon Ben-Noon, NeuroSense’s CEO, commented, “As we analyze the PARADIGM trial results, we continue … Continue reading “Exceptional Result”: NeuroSense Therapeutics Reports New Positive Data from ALS Trial